LACTIN-V is under clinical development by Osel and currently in Phase I for Human Papillomavirus Infections. According to GlobalData, Phase I drugs for Human Papillomavirus Infections have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LACTIN-V’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LACTIN-V overview
LACTIN-V is under development for the prevention and treatment of recurrent bacterial vaginosis, preterm birth and recurrent urinary tract infections (rUTI), human papilloma virus, cervical dysplasia and prevent cervical cancer. The therapeutic candidate is administered through vaginal route. The therapeutic candidate contains a single strain of Lactobacillus crispatus, CTV-05 and may aid in the treatment of infections. It was also under development for the treatment of Candida infection (yeast infections).
Osel overview
Osel develops live bio therapeutic products. The company’s clinical pipeline offers clinical stage and preclinical platform products. Its preclinical platform includes MucoCept technology platform for prevention of HIV infection. Osel’s LACTIN-V is a biotherapeutic product for women’s health disorders and patients with bacterial vaginosis and recurrent urinary tract infections. The company’s products are used in the therapeutic areas of women’s health and gastrointestinal tract disorders including recurrent urinary tract infections, recurrent bacterial vaginosis, inflammatory bowel diseases, and antibiotic-associated diarrhea, among others. It provides clinical trial services for validations of new therapeutic products. Osel is headquartered in Mountain View, California, the US.
For a complete picture of LACTIN-V’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
